Abstract
The aim of this workis to provide basic answers to questions related to the vaccination of solid organ transplant recipients based on the latest literature sources and clinical guidelines. Vaccination of solid organ transplants and persons in constant contact with them is a mandatory measure, the provision of which is a vital measure that effectively reduces the risk of death from COVID-19. Doubts about less effectiveness in conditions of immunosuppression or the potential risk of developing adverse reactions are significantly inferior to the risk of death and the development of severe complications. Until new data become available, the vaccination regimen must strictly comply with the instructions for medical use of the drug. Before transplantation, the patient should be examined according to the screening protocol, and also consulted by the transplant doctor who supervises him. It is possible that whole virion vaccines (CoviVac) have an advantage over others when vaccinating solid organ recipients, but clinical experience in this matter has not yet been obtained.
Highlights
Так имеет ли смысл вакцинация от COVID-19 у РТСО? Текущие данные об эффективности, полученные в результате клинических испытаний у иммунокомпрометированных пациентов, уверенно демонстрируют 100 % защиту от тяжелого течения COVID-19, которое может привести к интенсивной терапии или смерти [1–5]
The aim of this work is to provide basic answers to questions related to the vaccination of solid organ transplant recipients based on the latest literature sources and clinical guidelines
Vaccination of solid organ transplants and persons in constant contact with them is a mandatory measure, the provision of which is a vital measure that effectively reduces the risk of death from COVID-19
Summary
Так имеет ли смысл вакцинация от COVID-19 у РТСО? Текущие данные об эффективности, полученные в результате клинических испытаний у иммунокомпрометированных пациентов, уверенно демонстрируют 100 % защиту от тяжелого течения COVID-19, которое может привести к интенсивной терапии или смерти [1–5]. Вакцинация реципиентов трансплантатов солидных органов и лиц, находящихся с ними в постоянном контакте, является обязательным, жизненно важным мероприятием, эффективно снижающим риск смерти от COVID-19. Что цельновирионные вакцины (КовиВак) имеют преимущество перед прочими при вакцинации реципиентов солидных органов, но клинический опыт в этом вопросе ещё не получен. Для цитирования: Парабина Е.В., Константинов Д.Ю., Каабак М.М., Раппопорт Н.Н., Пушкин С.Ю., Селютин А.А., Навасардян А.С., Масликова У.В., Александрова В.Э., Яремин Б.И.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
